Greylin Investment Mangement Inc. boosted its stake in Amgen, Inc. (NASDAQ:AMGN) by 21.0% during the first quarter, according to its most recent filing with the SEC. The fund owned 2,475 shares of the medical research company’s stock after buying an additional 430 shares during the period. Greylin Investment Mangement Inc.’s holdings in Amgen were worth $406,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in AMGN. Norges Bank purchased a new position in shares of Amgen during the fourth quarter valued at about $1,016,913,000. FMR LLC boosted its position in shares of Amgen by 11.3% in the fourth quarter. FMR LLC now owns 40,789,786 shares of the medical research company’s stock valued at $5,963,875,000 after buying an additional 4,144,154 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in shares of Amgen during the fourth quarter valued at about $275,209,000. Asset Management One Co. Ltd. boosted its position in shares of Amgen by 426.2% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,331,811 shares of the medical research company’s stock valued at $194,885,000 after buying an additional 1,078,691 shares during the period. Finally, State Street Corp boosted its position in shares of Amgen by 2.8% in the fourth quarter. State Street Corp now owns 34,308,673 shares of the medical research company’s stock valued at $5,016,268,000 after buying an additional 919,966 shares during the period. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Shares of Amgen, Inc. (NASDAQ:AMGN) opened at 157.96 on Friday. The company has a market capitalization of $116.16 billion, a PE ratio of 15.00 and a beta of 1.15. The company’s 50 day moving average is $162.31 and its 200-day moving average is $158.61. Amgen, Inc. has a 52 week low of $133.64 and a 52 week high of $184.21.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.15. The company had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.60 billion. Amgen had a return on equity of 29.42% and a net margin of 33.59%. The business’s revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.90 earnings per share. On average, analysts expect that Amgen, Inc. will post $12.46 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 8th. Shareholders of record on Wednesday, May 17th will be paid a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date of this dividend is Monday, May 15th. Amgen’s dividend payout ratio is currently 44.92%.

ILLEGAL ACTIVITY NOTICE: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/05/19/amgen-inc-amgn-shares-bought-by-greylin-investment-mangement-inc.html.

AMGN has been the topic of several research analyst reports. Royal Bank of Canada set a $190.00 price objective on Amgen and gave the stock a “buy” rating in a research note on Tuesday, January 31st. Jefferies Group LLC cut Amgen from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $194.00 to $180.00 in a research note on Wednesday, April 5th. Vetr upgraded Amgen from a “buy” rating to a “strong-buy” rating and set a $184.82 price objective on the stock in a research note on Monday, March 27th. Credit Suisse Group AG restated a “hold” rating and set a $178.00 price objective on shares of Amgen in a research note on Tuesday, April 4th. Finally, Bank of America Corp upgraded Amgen from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $156.68 to $192.00 in a research note on Wednesday, February 1st. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. Amgen has an average rating of “Buy” and an average price target of $187.84.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.